Explore

Trendline Trendline
Vyome Holdings Reports Q1 2026 Financial Results with Net Loss and Strategic Developments

Vyome Holdings Reports Q1 2026 Financial Results with Net Loss and Strategic Developments

Vyome Holdings Reports Q1 2026 Financial Results with Net Loss and Strategic Developments
Trendline Trendline
Vyome Holdings Reports Q1 2026 Financial Results, Highlights Regulatory and Clinical Progress

Vyome Holdings Reports Q1 2026 Financial Results, Highlights Regulatory and Clinical Progress

Vyome Holdings Reports Q1 2026 Financial Results, Highlights Regulatory and Clinical Progress
Trendline Trendline
Vyome Holdings Reports Strong Q1 2026 Financials and Key FDA Filings

Vyome Holdings Reports Strong Q1 2026 Financials and Key FDA Filings

Vyome Holdings Reports Strong Q1 2026 Financials and Key FDA Filings
Trendline Trendline
GSK's Hepatitis B Drug Bepirovirsen Achieves High Cure Rates in Trials

GSK's Hepatitis B Drug Bepirovirsen Achieves High Cure Rates in Trials

GSK's Hepatitis B Drug Bepirovirsen Achieves High Cure Rates in Trials
Trendline Trendline
Veradermics to Present at June 2026 Investor Conferences, Highlighting Pattern Hair Loss Treatment

Veradermics to Present at June 2026 Investor Conferences, Highlighting Pattern Hair Loss Treatment

Veradermics to Present at June 2026 Investor Conferences, Highlighting Pattern Hair Loss Treatment
Trendline Trendline
FDA Initiates Priority Review for Sanofi's Gaucher Disease Drug Venglustat

FDA Initiates Priority Review for Sanofi's Gaucher Disease Drug Venglustat

FDA Initiates Priority Review for Sanofi's Gaucher Disease Drug Venglustat
Trendline Trendline
FDA Accepts BridgeBio's Application for Potential First Limb-Girdle Muscular Dystrophy Drug

FDA Accepts BridgeBio's Application for Potential First Limb-Girdle Muscular Dystrophy Drug

FDA Accepts BridgeBio's Application for Potential First Limb-Girdle Muscular Dystrophy Drug
Trendline Trendline
Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity
Trendline Trendline
FDA Approves AbbVie's Decnupaz for Rare Blood Cancer, Expanding Treatment Options

FDA Approves AbbVie's Decnupaz for Rare Blood Cancer, Expanding Treatment Options

FDA Approves AbbVie's Decnupaz for Rare Blood Cancer, Expanding Treatment Options
Trendline Trendline
Ono Pharma Presents Promising Phase 2 Data for ONO-2808 in Multiple System Atrophy

Ono Pharma Presents Promising Phase 2 Data for ONO-2808 in Multiple System Atrophy

Ono Pharma Presents Promising Phase 2 Data for ONO-2808 in Multiple System Atrophy
Trendline Trendline
Blackstone Group Secures $1.3 Billion Royalty Deal with Apogee Therapeutics for Eczema Drug Development

Blackstone Group Secures $1.3 Billion Royalty Deal with Apogee Therapeutics for Eczema Drug Development

Blackstone Group Secures $1.3 Billion Royalty Deal with Apogee Therapeutics for Eczema Drug Development
Trendline Trendline
Eli Lilly Expands Vaccine Portfolio Amid Moderna's Stock Surge Due to Hantavirus Concerns

Eli Lilly Expands Vaccine Portfolio Amid Moderna's Stock Surge Due to Hantavirus Concerns

Eli Lilly Expands Vaccine Portfolio Amid Moderna's Stock Surge Due to Hantavirus Concerns